1. The impact of therapeutic drug monitoring-based tamoxifen dose-reductions on endocrine side effects in patients with primary breast cancer. (November 2022) Authors: Buijs, S.; Braal, L.; Oomen-de Hoop, E.; van Rosmalen, M.; Drooger, J.; van Rossum-Schornagel, Q.; Vastbinder, M.; Koolen, S.; Jager, A.; Mathijssen, R. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗